F-Prime Capital (fka Fidelity Biosciences) is on record against 32 companies.
This thesis invests at the formation and early stages, focusing on rare diseases and gene therapy at the intersection of healthcare and tech. They favor technical feasibility over regulatory risk with a global geographic focus, syndicating founders through a Fidelity-backed engine.